TOP1

DNA topoisomerase 1 · P11387 · TOP1 on Sugi Atlas →

117,681 patent compounds predicted against TOP1, 72,445 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Topotecan (SCHEMBL3836)	1.00	19/20
Topotecan (SCHEMBL7247)	1.00	19/20
Topotecan (SCHEMBL7248)	1.00	19/20
Topotecan (SCHEMBL10278)	1.00	19/20
Lurtotecan (SCHEMBL13992)	1.00	19/20
Lurtotecan (SCHEMBL19208)	1.00	19/20
Gimatecan (SCHEMBL130586)	0.79	19/20
Exatecan (SCHEMBL26320)	0.60	19/20
Camptothecin (SCHEMBL6038)	1.00	18/20
Hydroxycamptothecin (SCHEMBL25875)	1.00	18/20
9-Aminocamptothecin (SCHEMBL26578)	1.00	18/20
Topotecan (SCHEMBL133645)	0.97	18/20
Rubitecan (SCHEMBL8640)	0.79	18/20
Belotecan (SCHEMBL18983)	0.79	18/20
7-Ethyl-10-Hydroxycamptothecin (SCHEMBL34018)	0.76	17/20
Rebeccamycin (SCHEMBL24695)	0.62	12/20
Irinotecan (SCHEMBL4034)	0.78	6/20
Irinotecan (SCHEMBL131381)	0.78	6/20
Irinotecan (SCHEMBL4033)	0.77	6/20
SCHEMBL109009	0.89	5/20

Clinical trials — most relevant to TOP1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study of Children With Refractory or Relapsed ALL	PHASE3	COMPLETED
Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer	PHASE2/PHASE3	COMPLETED
Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML	PHASE3	UNKNOWN
How To Evaluate The Efficiency And Safety Of Neoadjuvant Chemotherapy In Locally Advanced Cancer Cervix	PHASE2	UNKNOWN
PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers	PHASE1/PHASE2	COMPLETED
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients	PHASE1/PHASE2	COMPLETED
Efficacy and Safety Study of Sorafenib With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer	PHASE2	COMPLETED
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications	PHASE1/PHASE2	RECRUITING
Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Clinical and Pharmacological Study With 2B3-101 in Patients With Breast Cancer and Leptomeningeal Metastases	PHASE2	UNKNOWN
Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11)	PHASE2	COMPLETED
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma	PHASE2	COMPLETED
Topotecan for Irinotecan-Refractory SCLC	PHASE2	UNKNOWN
Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)	PHASE2	UNKNOWN
Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas	PHASE1	COMPLETED
A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas	PHASE1	COMPLETED
Indenoisoquinoline LMP400 for Advanced Solid Tumors and Lymphomas	PHASE1	COMPLETED
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer	PHASE1	ACTIVE_NOT_RECRUITING
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
Clinical Benefit of Topoisomerase Downregulation	PHASE1	COMPLETED
Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Relapsed or Refractory Small Cell Lung Cancer	PHASE1	COMPLETED
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors	PHASE1	RECRUITING
A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies	PHASE1	COMPLETED
Doxil Topotecan Doublet Cancer Study	PHASE1	COMPLETED
A Study of HDM2020 in Patients With Advanced Solid Tumors	PHASE1	RECRUITING
Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer	PHASE1	COMPLETED
64Cu/68Ga Labelled EB-ss-CPT PET/CT Scan in Colorectal Cancer	EARLY_PHASE1	UNKNOWN
Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer	nan	COMPLETED
A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer	nan	COMPLETED
Plant Extracted Natural Compounds Impact on Stage IV Breast Cancer Survival Time and Remission.	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a TOP1 binder may also engage these)

Protein	Name	Similarity
Q7YR26	—	1.000	Q7YR26 →
Q07050	—	1.000	Q07050 →
Q04750	—	1.000	Q04750 →
Q9WUL0	—	1.000	Q9WUL0 →
Q00313	—	0.999	Q00313 →
O17966	—	0.999	O17966 →
P41512	—	0.998	P41512 →
A0A0L0P4F8	—	0.997	A0A0L0P4F8 →
P30181	—	0.997	P30181 →
P07799	—	0.996	P07799 →
P93119	—	0.994	P93119 →
Q9FJ79	—	0.994	Q9FJ79 →
Q54RC3	—	0.994	Q54RC3 →
P04786	—	0.993	P04786 →
P41511	—	0.992	P41511 →
Q05D44	—	0.991	Q05D44 →
B4KF66	—	0.990	B4KF66 →
A9Q1D5	—	0.990	A9Q1D5 →
Q969P6	—	0.990	Q969P6 →
B4N0P7	—	0.990	B4N0P7 →
P30189	—	0.990	P30189 →
Q6C710	—	0.989	Q6C710 →
Q5RDE1	—	0.989	Q5RDE1 →
DHX29	ATP-dependent RNA helicase DHX29	0.989	landscape →
Q2VPH1	—	0.989	Q2VPH1 →
KAT7	Histone acetyltransferase KAT7	0.989	landscape →
A8XYX2	—	0.989	A8XYX2 →
Q6GM71	—	0.989	Q6GM71 →
Q8BMD7	—	0.989	Q8BMD7 →
Q6IM78	—	0.989	Q6IM78 →